Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. lifted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 9.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,394 shares of the biopharmaceutical company’s stock after purchasing an additional 1,108 shares during the quarter. Federated Hermes Inc.’s holdings in Agios Pharmaceuticals were worth $578,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AGIO. Nordea Investment Management AB increased its position in shares of Agios Pharmaceuticals by 13.0% during the first quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company’s stock worth $7,824,000 after purchasing an additional 30,764 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Agios Pharmaceuticals by 79.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 523,166 shares of the biopharmaceutical company’s stock valued at $11,651,000 after acquiring an additional 231,164 shares during the last quarter. Caxton Associates LP purchased a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $1,087,000. Norges Bank acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth about $6,826,000. Finally, Vanguard Group Inc. raised its stake in Agios Pharmaceuticals by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company’s stock worth $123,096,000 after purchasing an additional 59,851 shares during the period.

Insider Buying and Selling

In other news, CEO Brian Goff sold 11,091 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.93% of the stock is owned by insiders.

Agios Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ AGIO opened at $45.76 on Tuesday. The stock has a market capitalization of $2.60 billion, a PE ratio of -7.24 and a beta of 0.75. The stock has a fifty day simple moving average of $45.68 and a 200-day simple moving average of $39.34. Agios Pharmaceuticals, Inc. has a twelve month low of $19.80 and a twelve month high of $50.35.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm’s revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.51) EPS. On average, equities analysts predict that Agios Pharmaceuticals, Inc. will post -4.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AGIO shares. Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. The Goldman Sachs Group boosted their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a report on Tuesday, June 4th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $51.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.